Bell D M, Johns T E, Lopez L M
Clinical Pharmacy, School of Pharmacy, West Virginia University, Morgantown 26506, USA.
Ann Pharmacother. 1998 Apr;32(4):459-70. doi: 10.1345/aph.17084.
To review current literature regarding endothelial dysfunction in cardiovascular diseases and examine implications of these findings for the treatment of various cardiovascular disorders.
A MEDLINE search of basic science articles pertinent to understanding the role of the endothelium in the atherosclerotic process and of clinical trials examining the presence and treatment of impaired endothelium-dependent vascular relaxation was conducted.
Selected basic science articles and reviews were included to explain the foundation for subsequent clinical trials. All clinical trials examining the treatment of impaired endothelium-dependent vascular relaxation were reviewed.
Endothelial dysfunction characterized by impaired endothelium-dependent vascular relaxation is an early physiologic event in atherogenesis. Endothelial dysfunction in peripheral vasculature serves as a marker for impairment in coronary arteries. Techniques for measuring endothelium-dependent vascular relaxation are specific and have a high positive predictive value for coronary artery disease, but low sensitivity. Various pharmacologic agents have been used in an attempt to improve endothelial function, but only lipid-lowering agents and estrogen supplementation have been shown to improve endothelium-dependent vascular relaxation consistently. Treatments used in patients with heart failure or hypertension fail to demonstrate consistent improvement.
Endothelial dysfunction serves as a marker for cardiovascular disease, but pharmacologic treatment does not consistently restore normal endothelial function. Nevertheless, some of these agents are known to have positive clinical outcomes. Future research using these techniques will provide greater insight into the effects of many commonly used therapies for cardiovascular disease on the pathobiology of endothelial dysfunction.
回顾关于心血管疾病中内皮功能障碍的当前文献,并探讨这些研究结果对各种心血管疾病治疗的意义。
对MEDLINE进行检索,查找与理解内皮在动脉粥样硬化过程中的作用相关的基础科学文章,以及检测内皮依赖性血管舒张受损的存在及治疗情况的临床试验。
纳入选定的基础科学文章和综述以解释后续临床试验的基础。对所有检测内皮依赖性血管舒张受损治疗情况的临床试验进行综述。
以内皮依赖性血管舒张受损为特征的内皮功能障碍是动脉粥样硬化发生过程中的早期生理事件。外周血管系统中的内皮功能障碍可作为冠状动脉损伤的标志物。测量内皮依赖性血管舒张的技术具有特异性,对冠状动脉疾病有较高的阳性预测价值,但敏感性较低。已尝试使用各种药物来改善内皮功能,但只有降脂药物和补充雌激素已被证明能持续改善内皮依赖性血管舒张。用于心力衰竭或高血压患者的治疗未能显示出持续的改善效果。
内皮功能障碍是心血管疾病的一个标志物,但药物治疗并不能始终恢复正常的内皮功能。然而,已知其中一些药物具有积极的临床疗效。未来使用这些技术的研究将更深入地了解许多常用心血管疾病治疗方法对内皮功能障碍病理生物学的影响。